(Q38566507)

4 September 2017

1 reference

title

Current treatment of unresectable lung cancer (English)

1 reference

4 September 2017

J R Jett

1

1 reference

PubMed ID

8388526

4 September 2017

language of work or name

English

0 references

publication date

1 June 1993

1 reference

4 September 2017

1 reference

4 September 2017

68

1 reference

4 September 2017

603-611

1 reference

4 September 2017

6

1 reference

4 September 2017

Cancer statistics, 1992

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Staging systems of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the radiation therapy oncology group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Inoperable non-small cell lung cancer: radiation with or without chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Signiicant Effect of Adjuvant Chemotherapy on Survival in Locally Advanced Non-Small-Cell Lung Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: a Southeastern Cancer Study Group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Symptomatic treatmentversus combination chemotherapy for patients with extensive non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

A new international staging system for lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Oat cell carcinoma of the lung. A review of 138 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Improved Chemotherapy for Small-Cell Undifferentiated Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Survival after resection of small cell carcinoma of the bronchus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Long term survival after pulmonary resection for small cell carcinoma of the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Small cell lung cancer presenting as a solitary pulmonary nodule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Small cell carcinoma of the lung. A progress report of 15 years' experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients: a National Cancer Institute of Canada Clinical Trials Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a So

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

VP-16 and cisplatin as first-line therapy for small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

Role of radiation therapy in the management of lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960376-0

10.1016/S0025-6196(12)60376-0

7 January 2021

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

8388526